Aspergillosis Pipeline

DelveInsight’s, “Aspergillosis Pipeline Insight, 2026” report provides comprehensive insights about 5+ companies and 8+ pipeline drugs in Aspergillosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Aspergillosis Understanding

Aspergillosis Overview

Aspergillosis is a group of fungal infections caused by molds of the genus Aspergillus, most commonly Aspergillus fumigatus. These molds are widespread in the environment and are commonly found in soil, decaying vegetation, dust, compost piles, and indoor air. Most people inhale Aspergillus spores every day without becoming ill, but individuals with weakened immune systems, chronic lung diseases, or asthma are at increased risk of developing disease. Aspergillosis can present in several forms, including allergic bronchopulmonary aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA), aspergilloma (fungus ball), and invasive aspergillosis, which is the most severe form and can spread from the lungs to other organs such as the brain, kidneys, or heart. Symptoms vary depending on the type of infection and may include fever, cough, chest pain, wheezing, shortness of breath, and hemoptysis.

Aspergillosis is caused by inhalation of airborne spores produced by Aspergillus fungi. The disease develops when the immune system is unable to effectively clear these spores from the respiratory tract. People at highest risk include those undergoing chemotherapy, organ or stem cell transplantation, prolonged corticosteroid therapy, advanced HIV/AIDS, or treatment with immunosuppressive drugs. Individuals with preexisting lung conditions such as tuberculosis, chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis, or sarcoidosis are also more susceptible. Environmental exposure to construction dust, compost, or decaying organic matter may increase the fungal spore burden and contribute to infection risk.

The pathophysiology of aspergillosis depends on host immune status and underlying lung structure. After inhalation, Aspergillus spores reach the alveoli where they are normally eliminated by alveolar macrophages and neutrophils. In immunocompromised individuals, impaired phagocytic function allows fungal spores to germinate into hyphae, which invade pulmonary tissue and blood vessels, leading to tissue necrosis, thrombosis, hemorrhage, and dissemination to distant organs. In allergic forms such as ABPA, the disease is mediated by hypersensitivity reactions involving IgE and eosinophilic inflammation rather than direct tissue invasion. In chronic pulmonary aspergillosis, the fungus colonizes preexisting lung cavities and causes chronic inflammation and fibrosis.

Diagnosis of aspergillosis involves a combination of clinical evaluation, imaging studies, microbiological testing, and immunologic assays. Chest X-ray and computed tomography (CT) scans are commonly used to identify lung infiltrates, nodules, cavitary lesions, or fungal balls. Laboratory diagnosis may include sputum culture, bronchoalveolar lavage fluid analysis, fungal staining, and histopathological examination of tissue biopsies showing septate hyphae with acute-angle branching. Blood tests such as galactomannan antigen detection, beta-D-glucan assays, and Aspergillus-specific IgE or IgG antibody testing are useful depending on the disease subtype. Early diagnosis is critical, especially in invasive aspergillosis, because delayed treatment is associated with high mortality.

Treatment of aspergillosis depends on the form and severity of disease. Antifungal therapy is the mainstay of treatment for invasive and chronic pulmonary aspergillosis, with voriconazole considered the preferred first-line agent in many cases. Other antifungal agents such as isavuconazole, posaconazole, amphotericin B, and echinocandins may also be used depending on disease severity and patient tolerance. Allergic bronchopulmonary aspergillosis is typically managed with corticosteroids to reduce inflammation, sometimes combined with antifungal therapy to decrease fungal burden. Surgical removal may be considered for localized aspergillomas causing severe bleeding.

Management also includes reducing immunosuppression when possible and treating underlying lung disease.

"Aspergillosis Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Aspergillosis pipeline landscape is provided which includes the disease overview and Aspergillosis treatment guidelines. The assessment part of the report embraces, in depth Aspergillosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Aspergillosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Discover the latest Aspergillosis pipeline insights, emerging therapies, and clinical advancements shaping the future of treatment in 2026.

Aspergillosis Pipeline Report Highlights

The Aspergillosis companies and academics are working to assess challenges and seek opportunities that could influence Aspergillosis R&D. The therapies under development are focused on novel approaches to treat/improve Aspergillosis.

Aspergillosis Emerging Drugs Analysis

This segment of the Aspergillosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Aspergillosis Emerging Drugs

Fosmanogepix: Basilea Pharmaceutica

Fosmanogepix is an investigational broad-spectrum antifungal drug being developed by Basilea Pharmaceutica for invasive fungal infections including invasive aspergillosis. Fosmanogepix is a first-in-class antifungal agent available in both intravenous and oral formulations and has demonstrated activity against common Aspergillus species, including multidrug-resistant fungal strains. Its mechanism of action involves inhibition of the fungal enzyme Gwt1 (glycosylphosphatidylinositol-anchored wall transfer protein 1), which disrupts fungal cell wall integrity and prevents fungal growth and survival. Fosmanogepix has received multiple regulatory designations from the US FDA, including Fast Track Designation, Orphan Drug Designation for several invasive fungal infection indications including invasive aspergillosis, and Qualified Infectious Disease Product (QIDP) designation. In addition, the European Medicines Agency (EMA) granted orphan designation for invasive aspergillosis. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Aspergillosis.

Further product details are provided in the report……..

Aspergillosis Drug Therapeutic Assessment

This segment of the report provides insights about the different Aspergillosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Aspergillosis Players in Aspergillosis

There are approx. 5+ key companies which are developing the therapies Aspergillosis. The companies which have their Aspergillosis drug candidates in the most advanced stage, i.e. Phase III include, Basilea Pharmaceutica, and others.

Aspergillosis Clinical Trial Phases

DelveInsight’s report covers around 8+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Aspergillosis Drug Route of Administration

Aspergillosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Aspergillosis Product Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Aspergillosis Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Aspergillosis Clinical Trial Activities

The Aspergillosis pipeline report provides insights into different Aspergillosis clinical trials within phase II, I, preclinical and discovery stage. It also analyses Aspergillosis therapeutic drugs key players involved in developing key drugs.

Aspergillosis Pipeline Development Activities

The Aspergillosis clinical Trial analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Aspergillosis drugs.

Aspergillosis Pipeline Report Insights

• Aspergillosis Pipeline Analysis
• Aspergillosis Therapeutic Assessment
• Aspergillosis Unmet Needs
• Impact of Aspergillosis Drugs

Aspergillosis Pipeline Report Assessment

• Aspergillosis Pipeline Product Profiles
• Aspergillosis Therapeutic Assessment
• Aspergillosis Pipeline Assessment
• Aspergillosis Inactive drugs assessment
• Aspergillosis Market Unmet Needs

Discover actionable insights into the Aspergillosis market trends, epidemiology trends, and forecast through 2036 to stay ahead in emerging therapies.

Key Questions Answered In The Aspergillosis Pipeline Report:

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Aspergillosis drugs?
• How many Aspergillosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Aspergillosis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Aspergillosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Aspergillosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Aspergillosis Key Players

• Basilea Pharmaceutica
• F2G

Aspergillosis Key Products

• Fosmanogepix
• Olorofim

Explore comprehensive insights into Aspergillosis epidemiology trends, patient population forecasts, and growth opportunities through 2034 for strategic decision-making.